The safety of Adbry was evaluated in a pool of 5 randomized, double-blind, placebo-controlled trials in subjects with moderate-
to-severe atopic dermatitis, including three phase 3 studies ECZTRA 1, 2, and 3, a dose-finding trial, and a vaccine-response
trial¹
SAFETY POPULATION AT BASELINE
-
In these 5 atopic dermatitis trials, 1964 subjects were treated with subcutaneous injections of Adbry, with or without
concomitant topical corticosteroids (TCS). A total of 807 subjects were treated with Adbry for at least 1 year¹
-
ECZTRA 1 and ECZTRA 2 compared the safety of Adbry monotherapy to placebo through Week 52. ECZTRA 3 compared
the safety of Adbry+TCS to placebo+TCS through Week 32¹